Could a shot replace daily HIV pills? new trial tests injectable combo

NCT ID NCT07708727

Not yet recruiting Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether an injectable combination of two experimental drugs, GS-3242 and lenacapavir, can control HIV-1 as well as the daily pill Biktarvy. About 700 people with HIV who have never taken antiviral treatment will receive either the injectable regimen or the standard oral medication. The goal is to see if the shots can keep the virus at undetectable levels over several months, potentially offering a more convenient treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an injectable combination of GS-3242 and lenacapavir
What this could lead to: If successful, this could offer a long-acting injectable alternative to daily pills for people newly diagnosed with HIV, simplifying treatment and improving adherence.
What could go wrong: This is an early-to-mid-stage trial, so the injectable regimen may not prove as effective or safe as the current standard of care. Side effects from the injections or the drugs themselves are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV -1 INFECTION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.